Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Most people aren’t aware of the symptoms, especially if they’re otherwise healthy, because they don’t know that AFib can affect anyone!

Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...